NAV

Urapidil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Urapidil is a combination adrenergic antagonist and serotonin agonist given orally for the treatment of essential hypertension and intravenously in hypertensive emergencies.

Generic Name
Urapidil
DrugBank Accession Number
DB12661
Background

Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 387.484
Monoisotopic: 387.227039814
Chemical Formula
C20H29N5O3
Synonyms
  • Urapidil
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofHigh blood pressure (hypertension)••••••••••••
Treatment ofHypertensive emergency•••••••••••••••••••••• •••••••••• ••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Urapidil.
AbaloparatideAbaloparatide may increase the hypotensive activities of Urapidil.
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Urapidil.
AceclofenacThe therapeutic efficacy of Urapidil can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Urapidil can be decreased when used in combination with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
C02CA06 — Urapidil
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers
show 12 more
Substituents
Alkyl aryl ether / Amine / Aminophenyl ether / Aminopyrimidine / Aniline or substituted anilines / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Dialkylarylamine
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
A78GF17HJS
CAS number
34661-75-1
InChI Key
ICMGLRUYEQNHPF-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
IUPAC Name
6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1

References

General References
  1. BASG Product Information: Urapidil prolonged-release capsules [Link]
  2. AIFA Product Information: Ebrantil (urapidil hydrochloride) solution for intravenous infusion [Link]
PubChem Compound
5639
PubChem Substance
347828865
ChemSpider
5437
BindingDB
50237617
RxNav
39230
ChEBI
32278
ChEMBL
CHEMBL279229
ZINC
ZINC000001544805
Wikipedia
Urapidil

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentNontraumatic Intracerebral Hemorrhage, Multiple Localized1
3CompletedTreatmentCerebrovascular Diseases / Stroke, Acute1
3TerminatedTreatmentHypertension / Pre-Eclampsia1
3Unknown StatusTreatmentHypertension During Pre-Eclampsia1
1Unknown StatusTreatmentHypertension / Type B Aortic Dissection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral30 MG
CapsuleOral60 MG
Injection, solutionIntravenous
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral30 MG
Injection, solutionIntravenous50 mg/10ml
Capsule, extended releaseOral60 mg/1
Capsule, extended releaseOral90 mg/1
CapsuleOral
Injection, solutionIntravenous25 mg/5ml
Capsule, extended releaseOral
Injection, solutionParenteral
Injection, solution, concentrateIntravenous
SolutionIntravenous5 mg
Injection, solution25 MG
Injection, solution50 MG
Injection, solutionParenteral25 MG
Injection, solutionParenteral50 MG
Injection, solution, concentrateIntravenous100 MG
Capsule, extended releaseOral60 MG
Capsule, extended releaseOral90 MG
InjectionIntravenous
Injection, solutionIntravenous; Parenteral100 MG/20ML
Injection, solutionIntravenous; Parenteral25 MG/5ML
Injection, solutionIntravenous; Parenteral50 MG/10ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.541 mg/mLALOGPS
logP1.69ALOGPS
logP1.18Chemaxon
logS-2.9ALOGPS
pKa (Strongest Basic)8.11Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area68.36 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity119.37 m3·mol-1Chemaxon
Polarizability43.07 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0006-0900000000-2ccc838e7c2c252cb8ad
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0439000000-1f066af9035f53bb2d89
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0900000000-2ccc838e7c2c252cb8ad
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-395d1d378e00b9275895
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-7c3e18cbc3c9a347deed
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-586c2cccd4a3da6ae778
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0097000000-a4f60b89c82ffd04288a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0964000000-6c9c4a8f1ff721f38ae1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uk9-1594000000-666f654b837087e438aa
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-185.80992
predicted
DeepCCS 1.0 (2019)
[M+H]+188.72145
predicted
DeepCCS 1.0 (2019)
[M+Na]+196.76047
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 23:31 / Updated at June 08, 2021 11:32